anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Habiger of the United States Air Force who was Commander in Chief from 1996 to 1998 of United States Strategic Command; Richard Lugar, former senator for Indiana; Ash Carter, later United States Secretary of Defense, from 2015 to 2017; the US spent around $2.5 billion sending former nuclear missiles back to Russia in the early 1990s; Matthew Bunn, writer on nuclear security; the Soviet Union had 8 main radar sites in its early warning system - a main site in Latvia was dismantled, and nine satellites became three; General Vladimir Dvorkin (Russian), who wanted missiles to be less 'launchable', known as de-alerting; Lieutenant-General William Eldridge Odom, who was sceptical of 1990s meetings between US and Russian generals; Alexei Yablokov (Russian and the danger of suitcase nuclear devices, and Alexander Lebed; Armimex and a June 1997 commercial plot; William Cohen, United States Secretary of Defense from 1997 to 2001. Written by June Cross, directed by Dan Chambers, produced by David Dugan, made by Windfall Films and WGBH. Shown on PBS Frontline on 23 February 1999
In 1970, she began research at the Indian Institute of Technology, Kanpur (IIT Kanpur). In that year, she married Subramania Ranganathan, with whom she would go on to author Challenging problems in organic reaction mechanisms (1972), Art in biosynthesis: the synthetic chemist's challenge (1976), and Further challenging problems in organic reaction mechanisms (1980)—as well as editing an ongoing series titled "Current Organic Chemistry Highlights". She continued her research at IIT Kanpur on the basis of fellowships. Unwritten rules prevented her from joining the faculty because her husband was already a member. She began work at Regional Research Laboratory, Trivandrum in 1993, and at IICT, Hyderabad in 1998., where she became Deputy Director. During these years, she conducted ongoing collaborations with Isabella Karle at the U.S. Naval Research Laboratory. Darshan Ranganathan was diagnosed with breast cancer in 1997, and died on her 60th birthday, in 2001. The biennial "Professor Darshan Ranganathan Memorial Lecture", which is to be "delivered by a woman scientist who has made outstanding contributions in any field of Science and Technology" was established in her memory by her husband, in 2001.
Scurvy is a disease resulting from a deficiency of vitamin C. Without this vitamin, collagen made by the body is too unstable to perform its function and several other enzymes in the body do not operate correctly. Early symptoms are malaise and lethargy, progressing to shortness of breath, bone pain and susceptibility to bruising. As the disease progressed, it is characterized by spots on and bleeding under the skin and bleeding gums. The skin lesions are most abundant on the thighs and legs. A person with the ailment looks pale, feels depressed, and is partially immobilized. In advanced scurvy there is fever, old wounds may become open and suppurating, loss of teeth, convulsions and, eventually, death. Until quite late in the disease the damage is reversible, as healthy collagen replaces the defective collagen with vitamin C repletion. Notable human dietary studies of experimentally induced scurvy were conducted on conscientious objectors during World War II in Britain and on Iowa state prisoners in the late 1960s to the 1980s. Men in the prison study developed the first signs of scurvy about four weeks after starting the vitamin C-free diet, whereas in the earlier British study, six to eight months were required, possibly due to the pre-loading of this group with a 70 mg/day supplement for six weeks before the scorbutic diet was fed. Men in both studies had blood levels of ascorbic acid too low to be accurately measured by the time they developed signs of scurvy.
Screening for glaucoma is an integral part of a standard eye examination performed by optometrists and ophthalmologists. The workup for glaucoma involves taking a thorough case history, with the emphasis on assessment of risk factors. The baseline glaucoma evaluation tests include intraocular pressure measurement by using tonometry, anterior chamber angle assessment by optical coherence tomography, inspecting the drainage angle (gonioscopy), and retinal nerve fiber layer assessment with a fundus examination, measuring corneal thickness (pachymetry), and visual field testing.
Sources: en.wikipedia.org
==== Symbolic AI and its limits ==== Symbolic AI (or "GOFAI") simulated the high-level conscious reasoning that people use when they solve puzzles, express legal reasoning and do mathematics. It was highly successful at some "intelligent" tasks such as algebra or IQ tests. In 1976, Newell and Simon proposed the physical symbol systems hypothesis: "A physical symbol system has the necessary and sufficient means of general intelligent action." However, the symbolic approach failed on many tasks that humans solve easily, such as learning, recognising an object or commonsense reasoning. Moravec's paradox is the discovery that high-level "intelligent" tasks were easy for AI, but low level "instinctive" tasks were extremely difficult. Philosopher Hubert Dreyfus had argued since the 1960s that human expertise depends on embodied, situational know-how that is not representable as explicit symbolic rules rather than conscious symbol manipulation, and on having a "feel" for the situation, rather than explicit symbolic knowledge. Although his arguments had been ridiculed and ignored when they were first presented, eventually, AI research came to agree with him. The issue is not resolved: sub-symbolic reasoning can make many of the same inscrutable mistakes that human intuition does, such as algorithmic bias.
Evidence from the study of extant and extinct canids interpreted as supporting Bergmann's rule in the studied group at the interspecific level is presented by Chaves-Silveira et al. (2026). Evidence from the study of the fossil record of canids from the John Day Formation, indicative of stronger links of dietary behavior of the studied canids (as indicated by tooth wear) with lineage duration than with tooth morphology, is presented by Tanis, DeSantis & Terry (2026). Kort, Cavin & Wang (2026) describe the anatomy of the postcranial skeleton of Mesocyon coryphaeus, finding no evidence of cursorial adaptations seen in later canids, and interpret the studied canid as a likely ambush predator. Kropczyk & Marciszak (2026) report the discovery of fossil material of the corsac fox from the late Pleistocene strata from the Rogóżka Cave (Poland). Fossil material of Xenocyon lycaonoides representing one of the earliest records of this species worldwide is described from the early Pleistocene strata from the Gonghe Basin (Tibetan Plateau; China) by Huang et al. (2026). Frosali et al. (2026) interpret the shape and size of the frontal sinus in Canis etruscus, Canis mosbachensis and Canis borjgali as primarily influenced by the ecology of the studied canids, and interpret the morphology of the frontal sinus of the latter two species as indicative of higher proportion of meat in their diets compared to C. etruscus.
Structures that are intraperitoneal are generally mobile, while those that are retroperitoneal are relatively fixed in their location. Some structures, such as the kidneys, are "primarily retroperitoneal", while others such as the majority of the duodenum, are "secondarily retroperitoneal", meaning that structure developed intraperitoneally but lost its mesentery and thus became retroperitoneal.
RNH2 + [CH3SC(NH2)2]+X− → [RN(H)C(NH2)2]+X− + CH3SH The resulting guanidinium ions can often be deprotonated to give the guanidine. This approach is sometimes called the Rathke synthesis, in honor of its discoverer Bernhard Rathke.
A second set of four single-track tunnels, the East River Tunnels, were bored from the east under the East River, linking the new station to Queens, the PRR-owned Long Island Rail Road, and Sunnyside Yard in Queens, where trains would be maintained and assembled. Construction was completed on the Hudson River tunnels on October 9, 1906, and on the East River tunnels on March 18, 1908.
Sources: en.wikipedia.org
Leukotrienes are members of a family of eicosanoid inflammatory mediators produced in leukocytes by the oxidation of arachidonic acid (AA) and the essential fatty acid eicosapentaenoic acid (EPA) by the enzyme arachidonate 5-lipoxygenase. Leukotrienes use lipid signaling to convey information to either the cell producing them (autocrine signaling) or neighboring cells (paracrine signaling) in order to regulate immune responses. The production of leukotrienes is usually accompanied by the production of histamine and prostaglandins, which also act as inflammatory mediators. The role of one type of leukotriene (specifically, leukotriene D4) is to trigger contractions in the smooth muscles lining the bronchioles; their overproduction is a major cause of inflammation in asthma and allergic rhinitis. Leukotriene antagonists are used to treat these disorders by inhibiting the production or activity of leukotrienes.
== Early life == Daveigh Elizabeth Chase-Schwallier was born on July 24, 1990, in Las Vegas, Nevada, to Cathy Chase and John David Schwallier. She was young when her parents divorced. Each remarried, and she grew up with several half-siblings, including a younger half-brother named Cade. Chase later used her mother's maiden name professionally. She subsequently relocated with her mother to Albany, Oregon, where she performed in local talent shows and pageants. Her early vocal performances were centered on country music, for which she won a national vocal competition during her childhood. During a stay in Los Angeles, Chase began attending casting calls and booking minor roles, including national television advertising spots at age seven for the Campbell's Soup Company. Chase appeared in a regional theatrical production of the musical Utah! at the Tuacahn Amphitheatre in 1998, sharing the role of Norma Sanderson. She credited this stage experience with refining her live singing ability and performance presence.
Many variations of condensation reactions exist. Common examples include the aldol condensation and the Knoevenagel condensation, which both form water as a by-product, as well as the Claisen condensation and the Dieckman condensation (intramolecular Claisen condensation), which form alcohols as by-products.
A number of analogues are known, with the only other well-known compound to come out of the original 1950s research being clonitazene, which is much weaker than etonitazene (around 3x morphine). More recently since around late 2018 a number of designer analogues have started to appear on illicit markets around the world, with the most prominent compounds being metonitazene, isotonitazene and etazene, though others have continued to appear. Of these analogues, only etonitazene and clonitazene are explicitly listed under UN conventions and so are controlled throughout the world. The rest would only be illegal in countries such as the US, Australia and New Zealand that have laws equivalent to the Federal Analog Act. In the United States Etonitazene is a Schedule I narcotic controlled substance with a DEA ACSCN of 9624 and a 25 gram (7⁄8 oz) manufacturing quota as of 2022.
== Ethics == Much debate surrounds the topic of human enhancement and the means used to achieve one's enhancement goals. Ethical attitudes toward human enhancement can depend on many factors such as religious affiliation, age, gender, ethnicity, culture of origin, and nationality. In some circles the expression "human enhancement" is roughly synonymous with human genetic engineering, but most often it is referred to the general application of the convergence of nanotechnology, biotechnology, information technology and cognitive science (NBIC) to improve human performance. Since the 1990s, several academics (such as some of the fellows of the Institute for Ethics and Emerging Technologies) have risen to become advocates of the case for human enhancement while other academics (such as the members of President Bush's Council on Bioethics) have become outspoken critics. Advocacy of the case for human enhancement is increasingly becoming synonymous with "transhumanism", a controversial ideology and movement which has emerged to support the recognition and protection of the right of citizens to either maintain or modify their own minds and bodies; so as to guarantee them the freedom of choice and informed consent of using human enhancement technologies on themselves and their children. Their common understanding of the world can be seen from a physicist perspective rather than a biological perspective. Based on the idea of technological singularity, human enhancement is merging with technological innovation that will advance post-humanism.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.